In the phase 2 FASCINATE-1 trial, ASC40 at lower doses (25 or 50 mg/d) improved ALT and low-density lipoprotein (LDL) cholesterol levels, attenuated liver steatosis, fibrosis, lipotoxicity, dyslipidemia, and hepatic insulin resistance in obese NASH patients [26]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.